Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast ButtonSwitch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Stay Informed: Medical and Research Updates
Connect With Us!
 

 

BrightFocus-funded Researchers Design New Antibodies to Combat Alzheimer's and Parkinson's Disease

Antibodies Show Improved Ability to Prevent Toxic Protein Clusters in Cell Culture Assays

December 5, 2012

BrightFocus-Funded  Research: Novel Antibodies for Combating Alzheimer’s and Parkinson’s DiseaseResearch Summary:
Alzheimer's and Parkinson's disease are associated with inappropriate clustering of proteins called beta-amyloid and alpha-synuclein, respectively, which can lead to toxic brain deposits. BrightFocus-funded researcher and senior author Dr. Peter Tessier led a team that developed specialized antibodies to target and neutralize specific "sticky" sites on the protein where the clustering takes place. Based on their study of the 3D-structures and protein sequences of the sticky sites, the team designed antibodies that have about ten times the ability of a regular antibody to neutralize the toxic clustering of the misfolded Alzheimer's beta-amyloid protein (and alpha-synuclein for Parkinson's).

Significance:
Typically, only a small percentage of therapeutic antibodies delivered by injection into the blood can make it to target regions in the brain. Therefore, the antibodies that do make it past the blood-brain barrier would need to compensate for their low levels with a higher amount of activity. This need has now been addressed through the team's novel method of creating high-binding-activity antibodies—the number of proteins neutralized was improved from 1-2 proteins by each conventional antibody to 10 proteins by the new specialized antibodies. More testing needs to be done, but this new antibody design method could be applied to developing future therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.

View all news updates for Alzheimer's disease


Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.

Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.

Shop for a Cause YouTube Twitter Connect With Us Pinterest Google+